Neuralstem Enters Into Clinical Trial Research Agreement with
University of Pennsylvania
NEURALSTEM, INC. Creating Cures from the Frontiers of
Neuroscience -- Neuralstem, Inc. is a biotherapeutics company
utilizing its patented Human Neural Stem Cell technology to create
cures for diseases of the CNS (central nervous system).
(PRNewsFoto/
ROCKVILLE, Md., Dec. 17 /PRNewswire-
company, Neuralstem, Inc. (Amex: CUR), announced today that it has
entered into a Clinical Trial Research Agreement aimed at treating
patients suffering from Ischemic Spastic Paraplegia, a form of spinal
cord paralysis, with the Trustees of the University of Pennsylvania
through its Department of Anesthesiology and Critical Care. The
Institution'
of Anesthesiology, Hospital of the University of Pennsylvania.
"We are extremely pleased to be partnering with the University of
Pennsylvania Hospital, and Dr. Cheung's team on this important
milestone," said Neuralstem President & CEO Richard Garr. "They bring
world class experience and talent across the many disciplines that
are required for moving into the clinic for our first human trial."
"We at Penn are deeply committed to finding a way to help these
patients, and we are excited to be working with Neuralstem's cutting-
edge technology," commented Dr. Cheung. "I am proud to lead this very
experienced team that is already at work tackling the important and
exciting challenges we face in creating a safe and effective protocol
for the first human trials."
Ischemic Spastic Paraplegia (ISP) is a painful form of extreme
spasticity and rigidity that causes permanent and untreatable loss of
motor function and paralysis. ISP can result from surgery to repair
aortic aneurysms, an operation that is performed on thousands of
patients each year around the world.
About Neuralstem
Neuralstem's patent-protected technology enables, for the first
time, the ability to produce neural stem cells of the human brain and
spinal cord in commercial quantities, and the ability to control the
differentiation of these cells into mature, physiologically relevant
human neurons and glia.
The Company expects that its first Investigational New Drug (IND)
application will be for the treatment of Ischemic Paraplegia, a form
of paraplegia that sometimes results from the surgery to repair
aortic aneurysms and for which there is no effective treatment.
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia,
Traumatic Spinal Cord Injury, ALS, and Parkinson's disease. The
company's cells recently extended the life of rats with ALS (Lou
Gehrig's disease) in a paper published in the journal
TRANSPLANTATION, and were deemed viable for continued work in
neurodegenerative spinal conditions. Neuralstem cells also reversed
paralysis in rats with Ischemic Spastic Paraplegia, a form of
paralysis that can result from the surgery to repair aortic
aneurysms, as reported in NEUROSCIENCE (http://www.neurosci
ibro.com/). The company has also developed immortalized human neural
stem cells for in-vitro use in drug development for the academic and
pharmaceutical markets. For further information, please visit
http://www.neuralst
http://www.prnewswi
ACCT=104&STORY=
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Fed Cuts Rates Again - Think you pay you much for your mortgage? No SSN Required - Estimate New Payment.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment